Tags

Type your tag names separated by a space and hit enter

Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.
Scand J Gastroenterol. 2006 Oct; 41(10):1132-40.SJ

Abstract

OBJECTIVE

Gastro-oesophageal reflux disease (GORD) symptoms have a significant impact on patients' well-being. Onset of symptom relief is therefore an important consideration in GORD treatment. The primary objective was to compare the efficacy of rabeprazole (20 mg) and omeprazole (20 mg) regarding onset of heartburn control during the first 7 days of treatment in patients with erosive oesophagitis. Secondary objectives included maintenance of sustained heartburn control, control of other GORD symptoms (e.g. acid regurgitation, epigastric pain, dysphagia), effect on quality of life, patient satisfaction with treatment, and adverse events.

MATERIAL AND METHODS

In this multicentre, randomized, parallel-group, double-blind, comparative study, performed in Europe and Iceland, patients with endoscopically confirmed erosive oesophagitis were randomized to receive once-daily treatment with rabeprazole 20 mg (n=358) or omeprazole 20 mg (n=359) for 7 days. Symptoms were recorded (scored on a 5-point Likert scale) twice daily by the patients on their diary cards.

RESULTS

Median time to reach heartburn control was 1.5 days for both the rabeprazole and omeprazole groups (p<0.43). The results were similar between treatments for other study parameters. Both treatments were well tolerated.

CONCLUSIONS

Unlike previous studies, no significant differences were found between treatments with rabeprazole (20 mg) and omeprazole (20 mg) in this study. Further studies are needed to evaluate the potential benefit of fast-acting proton-pump inhibitors, such as rabeprazole, with respect to onset of symptom control in erosive GORD.

Authors+Show Affiliations

Department of Medical Gastroenterology, Glostrup University Hospital, Glostrup, Denmark. peter.bytzer@dadlnet.dkNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

16990197

Citation

Bytzer, Peter, et al. "Effect of Rabeprazole and Omeprazole On the Onset of Gastro-oesophageal Reflux Disease Symptom Relief During the First Seven Days of Treatment." Scandinavian Journal of Gastroenterology, vol. 41, no. 10, 2006, pp. 1132-40.
Bytzer P, Morocutti A, Kennerly P, et al. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. Scand J Gastroenterol. 2006;41(10):1132-40.
Bytzer, P., Morocutti, A., Kennerly, P., Ravic, M., & Miller, N. (2006). Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. Scandinavian Journal of Gastroenterology, 41(10), 1132-40.
Bytzer P, et al. Effect of Rabeprazole and Omeprazole On the Onset of Gastro-oesophageal Reflux Disease Symptom Relief During the First Seven Days of Treatment. Scand J Gastroenterol. 2006;41(10):1132-40. PubMed PMID: 16990197.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. AU - Bytzer,Peter, AU - Morocutti,Anna, AU - Kennerly,Peter, AU - Ravic,Miroslav, AU - Miller,Neil, AU - ,, PY - 2006/9/23/pubmed PY - 2007/1/16/medline PY - 2006/9/23/entrez SP - 1132 EP - 40 JF - Scandinavian journal of gastroenterology JO - Scand. J. Gastroenterol. VL - 41 IS - 10 N2 - OBJECTIVE: Gastro-oesophageal reflux disease (GORD) symptoms have a significant impact on patients' well-being. Onset of symptom relief is therefore an important consideration in GORD treatment. The primary objective was to compare the efficacy of rabeprazole (20 mg) and omeprazole (20 mg) regarding onset of heartburn control during the first 7 days of treatment in patients with erosive oesophagitis. Secondary objectives included maintenance of sustained heartburn control, control of other GORD symptoms (e.g. acid regurgitation, epigastric pain, dysphagia), effect on quality of life, patient satisfaction with treatment, and adverse events. MATERIAL AND METHODS: In this multicentre, randomized, parallel-group, double-blind, comparative study, performed in Europe and Iceland, patients with endoscopically confirmed erosive oesophagitis were randomized to receive once-daily treatment with rabeprazole 20 mg (n=358) or omeprazole 20 mg (n=359) for 7 days. Symptoms were recorded (scored on a 5-point Likert scale) twice daily by the patients on their diary cards. RESULTS: Median time to reach heartburn control was 1.5 days for both the rabeprazole and omeprazole groups (p<0.43). The results were similar between treatments for other study parameters. Both treatments were well tolerated. CONCLUSIONS: Unlike previous studies, no significant differences were found between treatments with rabeprazole (20 mg) and omeprazole (20 mg) in this study. Further studies are needed to evaluate the potential benefit of fast-acting proton-pump inhibitors, such as rabeprazole, with respect to onset of symptom control in erosive GORD. SN - 0036-5521 UR - https://www.unboundmedicine.com/medline/citation/16990197/Effect_of_rabeprazole_and_omeprazole_on_the_onset_of_gastro_oesophageal_reflux_disease_symptom_relief_during_the_first_seven_days_of_treatment_ L2 - http://www.tandfonline.com/doi/full/10.1080/00365520600615781 DB - PRIME DP - Unbound Medicine ER -